Huibo Lian1, Rong Yang1, Tingsheng Lin1, Wei Wang1, Gutian Zhang1, Hongqian Guo2. 1. Department of Urology, Affiliated Drum Tower Hospital of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, People's Republic of China. 2. Department of Urology, Affiliated Drum Tower Hospital of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, People's Republic of China. doctorghq@gmail.com.
Abstract
PURPOSE: To present the intermediate results of the use of third-generation cryotherapy as salvage treatment for locally recurrent prostate cancer after radiation therapy. METHODS: From January 2006 to July 2010, 32 patients with locally recurrent prostate cancer after radiotherapy underwent salvage cryoablation using third-generation technology. Biochemical recurrence-free survival (BRFS) was defined as the time period from salvage treatment to the date of biochemical recurrence (Phoenix definition of nadir +2 ng/ml). Complications were classified as grades 1-5 according to the modified Clavien system. Multivariate logistic regression analysis was performed to identify potential risk factors associated with recurrence after salvage cryotherapy. RESULTS: The median follow-up was 63 months (range 38-92). Mild complications (grades 1 and 2) included mild incontinence (9.4 %), acute rectal pain (31.3 %), hematuria (6.3 %), scrotal edema (9.4 %), urinary tract infection (3.1 %), lower urinary tract symptoms (15.6 %) and erectile dysfunction (57.1 %). Severe events (grade 3) included severe incontinence (3.1 %) and urethral sloughing (3.1 %). The rate of rectourethral fistula and urinary retention was absent. The 5-year overall survival was 92.3 %. The 5-year cancer-specific survival was 100 %. The 5-year BRFS rate using the Phoenix definition was 43.5 %. A multivariate analysis disclosed that PSA at cryoablation was the only predictive factor for biochemical recurrence. CONCLUSIONS: Salvage cryotherapy using third-generation technology offers a safe and effective alternative for locally recurrent prostate cancer after radiation therapy. Additional studies with longer follow-up are necessary to determine the sustained efficacy of this procedure.
PURPOSE: To present the intermediate results of the use of third-generation cryotherapy as salvage treatment for locally recurrent prostate cancer after radiation therapy. METHODS: From January 2006 to July 2010, 32 patients with locally recurrent prostate cancer after radiotherapy underwent salvage cryoablation using third-generation technology. Biochemical recurrence-free survival (BRFS) was defined as the time period from salvage treatment to the date of biochemical recurrence (Phoenix definition of nadir +2 ng/ml). Complications were classified as grades 1-5 according to the modified Clavien system. Multivariate logistic regression analysis was performed to identify potential risk factors associated with recurrence after salvage cryotherapy. RESULTS: The median follow-up was 63 months (range 38-92). Mild complications (grades 1 and 2) included mild incontinence (9.4 %), acute rectal pain (31.3 %), hematuria (6.3 %), scrotal edema (9.4 %), urinary tract infection (3.1 %), lower urinary tract symptoms (15.6 %) and erectile dysfunction (57.1 %). Severe events (grade 3) included severe incontinence (3.1 %) and urethral sloughing (3.1 %). The rate of rectourethral fistula and urinary retention was absent. The 5-year overall survival was 92.3 %. The 5-year cancer-specific survival was 100 %. The 5-year BRFS rate using the Phoenix definition was 43.5 %. A multivariate analysis disclosed that PSA at cryoablation was the only predictive factor for biochemical recurrence. CONCLUSIONS: Salvage cryotherapy using third-generation technology offers a safe and effective alternative for locally recurrent prostate cancer after radiation therapy. Additional studies with longer follow-up are necessary to determine the sustained efficacy of this procedure.
Authors: John W Robinson; Bryan J Donnelly; Kerry Coupland; Jodi E Siever; John C Saliken; Cheryl Scott; P M A Brasher; D Scott Ernst Journal: Urol Oncol Date: 2006 Nov-Dec Impact factor: 3.498
Authors: L L Pisters; A C von Eschenbach; S M Scott; D A Swanson; C P Dinney; C A Pettaway; R J Babaian Journal: J Urol Date: 1997-03 Impact factor: 7.450
Authors: Philippe E Spiess; Aaron E Katz; Joseph L Chin; Duke Bahn; Jeffrey K Cohen; Katsuto Shinohara; Mike Hernandez; Julie Bossier; Wassim Kassouf; Louis L Pisters Journal: BJU Int Date: 2009-11-17 Impact factor: 5.588
Authors: Duke K Bahn; Fred Lee; Paul Silverman; Eric Bahn; Robert Badalament; Anil Kumar; Jeffrey Greski; John C Rewcastle Journal: Clin Prostate Cancer Date: 2003-09
Authors: Leszek Miszczyk; Małgorzata Stąpór-Fudzińska; Marcin Miszczyk; Bogusław Maciejewski; Andrzej Tukiendorf Journal: Technol Cancer Res Treat Date: 2018-01-01